AZ readies mid-stage CytoFab trial

AstraZeneca has confirmed plans to begin Phase II clinical trials of CytoFab for severe sepsis. That's good news for BTG, which acquired CytoFab when it merged with Protherics. "AstraZeneca's continued commitment to CytoFab is a clear positive for BTG, especially considering the investment required for such a high risk indication," said Nomura Code Securities analyst Samir Devani. Report

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.